S'abonner

Influence of Obesity on Outcomes in Atrial Fibrillation: Yet Another Obesity Paradox - 19/08/11

Doi : 10.1016/j.amjmed.2009.11.026 
Apurva O. Badheka, MD a, Ankit Rathod, MD a, Mohammad A. Kizilbash, MD b, Neha Garg, MD a, Tamam Mohamad, MD b, Luis Afonso, MD a, b, Sony Jacob, MD a, b,
a Department of Internal Medicine, Wayne State University, Harper University Hospital, Detroit, Mich 
b Division of Cardiology/Electrophysiology, Wayne State University, Harper University Hospital, Detroit, Mich 

Requests for reprints should be addressed to Sony Jacob, MD, 8 Webber South, Harper University Hospital, Division of Cardiology, Wayne State University, 3990 John R, Detroit, MI 48201

Abstract

Background

Obese patients have favorable outcomes in congestive heart failure, hypertension, peripheral vascular disease, and coronary artery disease. Obesity also has been linked with increased incidence of atrial fibrillation, but its influence on outcomes in atrial fibrillation patients has not been investigated. The objective of this research is to investigate the effect of obesity on outcomes in atrial fibrillation.

Methods

The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study was one of the largest multicenter trials of atrial fibrillation, with 4060 patients. Subjects were randomized to rate versus rhythm-control strategy. We performed a post hoc analysis of the National Heart, Lung and Blood Institute limited access dataset of atrial fibrillation patients who had body mass index (BMI) data available in the AFFIRM study. BMI data were not available on 1542 patients. Patients with BMI ≥18.5 were split into normal (18.5-25), overweight (25-30), and obese (>30) categories as per BMI (kg/m2). Multivariate Cox proportional hazards regression was used on the eligible 2492 patients. End points were all-cause mortality and cardiovascular mortality.

Results

Over three fourths of all patients in our cohort were overweight or obese. There were 304 deaths (103 among normal weight, 108 among overweight, and 93 among obese) and 148 cardiovascular deaths (54 among normal weight, 41 among overweight, and 53 among obese) over a mean period of 3 years of patient follow-up. On multivariate analysis, overweight (hazard ratio [HR] 0.64; 95% confidence interval [CI], 0.48-0.84; P=.001) and obese (HR 0.80; 95% CI, 0.68-0.93; P=.005) categories were associated with lower all-cause mortality as compared with normal weight. Overweight (HR 0.40; 95% CI, 0.26-0.60; P <.001) and obese patients (HR 0.77; 95% CI, 0.62-0.95; P=.01) also had lower cardiovascular mortality as compared with the normal weight patients.

Conclusions

Although in prior studies, obesity has been associated with increased risk of atrial fibrillation, an obesity paradox exists for outcomes in atrial fibrillation. Obese patients with atrial fibrillation appear to have better long-term outcomes than nonobese patients.

Le texte complet de cet article est disponible en PDF.

Keywords : Atrial fibrillation, Obesity, Reverse epidemiology


Plan


 Funding: None.
 Conflict of Interest: None of the authors have any financial disclosure or conflict of interest to report. None of the study authors are associated with the National Heart, Lung and Blood Institute or the Atrial Fibrillation Follow-up Investigation of Rhythm Management trial.
 Authorship: All authors had access to the data and were involved in the conception, data analysis, and writing of the manuscript.


© 2010  Elsevier Inc. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 123 - N° 7

P. 646-651 - juillet 2010 Retour au numéro
Article précédent Article précédent
  • Underuse of Oral Anticoagulants in Atrial Fibrillation: A Systematic Review
  • Isla M. Ogilvie, Nick Newton, Sharon A. Welner, Warren Cowell, Gregory Y.H. Lip
| Article suivant Article suivant
  • Internal Carotid Artery Aneurysm Discovered by Palpation of Asymmetric Pulses
  • Pierre Charbel Atallah, Pierre Atallah, Vikram Kashyap

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.